The company filed a lawsuit Monday in the US District Court for the District of Columbia alleging the US Health Resources and Services Administration acted unlawfully when it denied Sanofi’s 340B Credit Model—a system that would change the way health providers under the 340B Drug Pricing Program purchase drugs.
Manufacturers under the federal 340B program are required to discount drugs for covered entities, which are qualifying hospitals, clinics, and ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.